WEGOVY (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver This indication is approved based on improvement of MASH and liver scarring (fibrosis)
Applications Claiming Priority (2) Publications (1) Family ID=83915780 Family Applications (1) Country Status (1) Cited By (2) Citations (12) 2022 2022-06-20 CN CN202210698338.3A patent/CN115322250A/en active Pending
Low blood sugar episodes can present with weakness, tremor, confusion, and sweating
Persistent lumps may also indicate early lipohypertrophy, which is a signal to stop injecting in that area and improve your rotation habits
Di Odoardo LAF, Zucchetti O, Sciatti E, DIsa S, DElia E, Senni M